In a xenograft model of mice using human hepatocellular carcinoma, it was found that human bone marrow MSCs were able to enhance tumor angiogenesis due to the action of TGF-β1, the secretion of which increased in tumor cells following the intravenous administration of MSCs. Here, TGFB1 is linked to neoplasm.